GT Biopharma Appoints New CEO

GT Biopharma announced that Shawn M. Cross will become chairman and chief executive officer effective February 15, 2018.

Mr. Cross has held the position of president and chief operating officer of GTBP since November 16, 2017. The plan to add the new positions to his current duties was initiated by the Company’s board of directors to prepare for the company’s next phase of growth. 

Mr. Cross will lead GTBP through NASDAQ capital markets listing process, attract institutional investment and analyst coverage to the company, and guide development of its neurology portfolio and its first TriKE into human clinical testing in 2018.

He is an internationally recognized healthcare investment banker specializing in the biopharmaceutical sector with over 20 years of experience and has completed dozens of capital markets and strategic transactions for growth-oriented biopharmaceutical companies. Most recently, he was managing director, Head of Biotechnology Investment Banking at Deutsche Bank Securities Inc. 

Cross said, “I continue to see a great deal of promise in GT Biopharma’s pipeline of immuno-oncology and neurology therapeutics and am honored to become Chairman and Chief Executive Officer of such a dynamic company. I look forward to announcing additional experienced members to our management team and board in the coming weeks.”